PTC Therapeutics filings document a Delaware biopharmaceutical company with common stock listed on the Nasdaq Global Select Market under PTCT. Its Form 8-K reports cover quarterly and annual financial results, Regulation FD disclosures, product and pipeline updates, FDA-related communications, and board or compensation matters.
Proxy materials describe annual meeting governance, director elections, executive compensation, equity awards and related shareholder matters. The filing record also includes disclosures tied to rare-disease programs such as Sephience™ (sepiapterin), votoplam and Translarna™ (ataluren), along with the company’s capital structure and public-company reporting obligations.
PTC Therapeutics, Inc. (PTCT) director Michael Schmertzler reported that Section Six Partners, L.P., of which he is a general and limited partner, sold 2,500 common shares in two transactions on October 7, 2026: 2,447 shares at a weighted average $63.38 per share and 53 shares at $63.95. The 2,447-share price reflects multiple trades ranging from $62.89 to $63.88. Both sales were made under the partnership's written Rule 10b5-1 plan adopted May 14, 2026. The shares were held by the partnership; Schmertzler disclaims beneficial ownership except to the extent of his pecuniary interest. A separate entry lists 163,266 shares held directly.
PTC Therapeutics, Inc. (PTCT) is the issuer for a proposed sale by officer Mark Elliott Boulding of 192 common shares, with an aggregate market value of $12,338.84. Fidelity Brokerage Services LLC is listed as broker, and the approximate sale date is October 9, 2026, on Nasdaq. The shares were acquired from the issuer through a stock option exercise for cash on October 9, 2026.
PTC Therapeutics’ executive vice president and CLO Mark Elliott Boulding exercised options for 1,638 shares on October 5, 2026, at a $39.42 exercise price, then sold those shares at a weighted average $64.03. On October 6, he exercised options for 435 shares at $39.42 and sold them at a weighted average $64.16. The transactions were effected pursuant to a written Rule 10b5-1 plan adopted September 10, 2025. The sales comprised multiple trades at $64.00–$64.34 on October 5 and $64.00–$64.90 on October 6.
A Rule 144 notice concerning PTC Therapeutics, Inc. lists Section Six Partners, L.P. as proposing to sell 10,000 common shares, with an aggregate market value of $643,500 and an approximate sale date of October 7, 2026. Merrill Lynch is listed as broker; the notice reports 83,460,802 issuer shares outstanding.
Michael Schmertzler, a member of PTC Therapeutics’ Board of Directors, is a general and limited partner of Section Six Partners. He disclaims beneficial ownership of the partnership’s shares except to the extent of his pecuniary interest. The notice lists eight prior sales by the partnership from August 19 through September 17, 2026, in individual blocks of 10,000 or 12,500 shares.
PTC Therapeutics, Inc. officer Mark Boulding gave notice of a proposed sale of 435 common shares, with an aggregate market value of $27,907.59 and an approximate sale date of October 6, 2026. The notice identifies Fidelity Brokerage Services LLC as broker and lists the shares as acquired from the issuer through a stock option exercise for cash.
PTC Therapeutics, Inc. officer Mark Boulding reported a proposed sale of 1,638 common shares on October 5, 2026, with an aggregate market value of $104,883.45. He also reported sales of 5,079 common shares for $432,115.62 on July 6, 2026, and 2,813 common shares for $204,123.09 on August 17, 2026.
PTC Therapeutics, Inc. director Glenn Jr. MD, PhD Steele exercised 12,000 options at an exercise price of $11.23 per share on September 30, 2026, acquiring 12,000 common shares, then sold 12,000 common shares at $65.16 per share that day. The transactions were effected under a written Rule 10b5-1 plan adopted March 9, 2026. The options were currently exercisable; the reported option balance after the transaction was 0.
PTC Therapeutics, Inc. (PTCT) director Glenn D. Steele Jr. reported a proposed sale of 12,000 common shares with an aggregate market value of $781,920.00. Fidelity Brokerage Services LLC is listed as the broker, and September 30, 2026, is the approximate sale date. The notice also lists 12,000 common shares acquired from the issuer through a stock option exercise, with cash payment, on September 30, 2026.
PTC Therapeutics, Inc. (PTCT) announced completion of its acquisition of ST-920, a BLA-stage, one-time administered AAV gene therapy product candidate for Fabry disease, from Sangamo Therapeutics. PTC plans to complete a rolling biologics license application submission to the U.S. Food and Drug Administration for accelerated approval of ST-920 in the fourth quarter of 2026.
The planned BLA is based on evidence of meaningful favorable clinical effect on renal function and a safety and tolerability profile over 52 weeks in the Phase 1/2 STAAR study. PTC also expects to pursue regulatory approval of ST-920 outside the United States. ST-920 (isaralgagene civaparvovec) has received multiple regulatory designations, including Orphan Drug, Fast Track and RMAT from the FDA, Orphan Medicinal Product designation and PRIME eligibility from the European Medicines Agency, and access via the U.K. Innovative Licensing and Access Pathway.
PTC THERAPEUTICS, INC. (PTCT) director Michael Schmertzler reported the indirect sale of 20,000 shares of common stock on September 16–17, 2026 through Section Six Partners, L.P., an entity of which he is a general and limited partner. The trades were executed under a Rule 10b5-1 plan adopted by Section Six Partners, L.P. on May 14, 2026, at weighted-average prices ranging from $65.99 to $68.84 per share in multiple transactions. Schmertzler disclaims beneficial ownership of the partnership-held shares except to the extent of his pecuniary interest, and separately reports 163,266 shares of PTCT common stock held directly.